EP1827466A2 - Composition and method for facilitating the healing of non-healing and slow-healing wounds and ulcerations - Google Patents
Composition and method for facilitating the healing of non-healing and slow-healing wounds and ulcerationsInfo
- Publication number
- EP1827466A2 EP1827466A2 EP05826664A EP05826664A EP1827466A2 EP 1827466 A2 EP1827466 A2 EP 1827466A2 EP 05826664 A EP05826664 A EP 05826664A EP 05826664 A EP05826664 A EP 05826664A EP 1827466 A2 EP1827466 A2 EP 1827466A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- healing
- curcumin
- arginine
- composition
- nitroglycerin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Definitions
- the present invention generally relates to an
- the present invention relates to an
- Wound healing is a highly complex process, involving
- Endothelial nitric oxide synthase eNOS/iNOS
- a healthy blood supply (local and systemic);
- Type II diabetes is one such factor, and is the most
- the CDC estimates the diabetes, both diagnosed
- Diabetes is a prevalent disease and an ever-growing
- Diabetes is reportedly
- diabetics have a fifteen percent
- diabetic foot ulcers will heal within six months-
- compositions or methods of treatment either alone or in
- composition and use thereof .obviates the need for
- the present invention provides a composition
- composition of the present invention comprises,
- aloe vera constituents are instrumental in maintaining
- composition was applied twice daily. After a total of
- Patient F had lost one finger tip to an ulcer and poor
- Patient F has an open scalp lesion of approximately
- Patient G had a developing lesion between her
- composition comprises: nitroglycerin (Nitrobid) 2%
- Curcumin Powder 95% (or a curcumin-containing ingredient,
- composition is formed as the triturate powders and wet
- the treatment protocol essentially involves leaving
- the wound is typically
- the present method increases blood flow to
- Nitroglycerin is a nitrate that has been approved by
- Nitroglycerin is a nitric oxide (NO) donor.
- NO is a nitric oxide (NO) donor.
- Nitroglycerin acts by donating nitric oxide, which
- microvessels microvessels .
- Non healing wounds especially in diabetic and
- Curcumin (diferuloylmethane) , is a natural product
- Curcuma longa (tumeric) plant Curcuma longa (tumeric) . Curcumin promotes wound
- Curcumin significantly accelerates wound healing as
- Curcumin increases eNos/iNOS within a wound.
- NO is a vital factor in wound healing
- iNOS inducible nitric oxide synthetase
- eNOS endothelial NO
- iNOS induced in large
- Curcumin enhances macrophage production (white
- Curcumin demonstrates anti-inflammatory action
- curcutninoids in tumeric demethoxy- or
- Curcumin helps fight off pathogens acting as a
- Neisseria gonorrhoeae-induced NF-kappaB signaling Neisseria gonorrhoeae-induced NF-kappaB signaling.
- Curcumin has antimicrobial action (Journal of
- Curcumin has antifungal properties - 100% phytotoxic
- Curcumin is anti-inflammatory, antioxidant,
- Curcumin shows antibacterial, anti-inflammatory, and antineoplastic activity (J Pharmacologic Pharmacology
- Curcumin enhances angiogenesis (Journal of
- Angiogenesis is a prerequisiste for wound healing.
- Curcumin is frequently studied for it's role in enhancing
- Curcumin has been shown in many animal studies to
- Topical curcumin enhances cutaneous wound healing in
- curcumin has been used in
- dimerization occurs rapidly, on a timescale of minutes.
- the dimmer is stable (Journal of Biological
- Arginine is a substrate to make NO, a particular
- amino acid L-arginine is the only substrate for nitric oxide
- NO is a small radical, formed directly from the
- Curcumin by inflammatory cells, mainly macrophages. Curcumin
- the wound site (or any other tissue site of
- nitroglycerine "opens the door"
- the primary active ingredients are Nitroglycerin, Arginine, and
- Nitroglycerin is in the form of two percent ointment
- compositions of the present invention may be prepared
- composition for remediation of dermal anomalies Composition for remediation of dermal anomalies
- the formed composition may then be applied topically
- Curcumin is presently shown at an.08%
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/992,623 US7731993B2 (en) | 2004-11-17 | 2004-11-17 | Composition for treating a dermal anomaly |
US10/992,636 US20060105027A1 (en) | 2004-11-17 | 2004-11-17 | Method for treating skin ulcers |
PCT/US2005/041708 WO2006055726A2 (en) | 2004-11-17 | 2005-11-17 | Composition and method for facilitating the healing of non-healing and slow-healing wounds and ulcerations |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1827466A2 true EP1827466A2 (en) | 2007-09-05 |
EP1827466A4 EP1827466A4 (en) | 2009-11-11 |
Family
ID=36407755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05826664A Withdrawn EP1827466A4 (en) | 2004-11-17 | 2005-11-17 | Composition and method for facilitating the healing of non-healing and slow-healing wounds and ulcerations |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1827466A4 (en) |
JP (1) | JP2008520694A (en) |
AU (1) | AU2005307736A1 (en) |
BR (1) | BRPI0517731A (en) |
CA (1) | CA2588119A1 (en) |
IL (1) | IL183117A0 (en) |
WO (1) | WO2006055726A2 (en) |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0665647B2 (en) * | 1985-06-12 | 1994-08-24 | 株式会社三和化学研究所 | Transdermal treatment agent |
US5196185A (en) * | 1989-09-11 | 1993-03-23 | Micro-Collagen Pharmaceutics, Ltd. | Collagen-based wound dressing and method for applying same |
US5698589A (en) * | 1993-06-01 | 1997-12-16 | International Medical Innovations, Inc. | Water-based topical cream containing nitroglycerin and method of preparation and use thereof |
US5401504B1 (en) * | 1993-12-28 | 1998-04-21 | Univ Mississippi Medical Cente | Use of tumeric in wound healing |
US5925376C1 (en) * | 1994-01-10 | 2001-03-20 | Madalene C Y Heng | Method for treating psoriasis using selected phosphorylase kinase inhibitor and additional compounds |
PT1051972E (en) * | 1994-05-27 | 2007-12-07 | Strakan Internat Ltd Uma Socie | Nitric oxide donor composition and method for treatment of anal disorders |
US5543430A (en) * | 1994-10-05 | 1996-08-06 | Kaesemeyer; W. H. | Method and formulation of stimulating nitric oxide synthesis |
US5891472A (en) * | 1996-11-19 | 1999-04-06 | Meri Charmyne Russell | Treatment of equine laminitis |
JP3667027B2 (en) * | 1997-03-06 | 2005-07-06 | 株式会社ノエビア | Topical skin preparation |
JP4489289B2 (en) * | 1998-02-27 | 2010-06-23 | シンクロニュ−ロン,エルエルシ− | Method for treating an anal pain condition and composition therefor |
US6627632B2 (en) * | 1998-12-14 | 2003-09-30 | Cellegy Pharmaceuticals, Inc. | Compositions and methods for the treatment of anorectal disorders |
US20030104033A1 (en) * | 2001-07-13 | 2003-06-05 | Lai Chon-Si | Enteral formulations |
US20030091601A1 (en) * | 2001-11-13 | 2003-05-15 | Abat Inc. | Use of topical arginine to enhance wound healing |
-
2005
- 2005-11-17 AU AU2005307736A patent/AU2005307736A1/en not_active Abandoned
- 2005-11-17 BR BRPI0517731-6A patent/BRPI0517731A/en not_active IP Right Cessation
- 2005-11-17 CA CA002588119A patent/CA2588119A1/en not_active Abandoned
- 2005-11-17 EP EP05826664A patent/EP1827466A4/en not_active Withdrawn
- 2005-11-17 JP JP2007543244A patent/JP2008520694A/en active Pending
- 2005-11-17 WO PCT/US2005/041708 patent/WO2006055726A2/en active Application Filing
-
2007
- 2007-05-10 IL IL183117A patent/IL183117A0/en unknown
Non-Patent Citations (10)
Title |
---|
ALI IBN ABBAS MAJOOSI: "Dawa-e-Afs", KEY ATTRIBUTES OF TKDL AH3/1631, pages 1 - 2, XP003025233 |
ALI IBN ABBAS MAJOOSI: "Zaroor-e-Sibr", KEY ATTRIBUTES OF TKDL AH3/1627, pages 1 - 2, XP003025232 |
AMINUDDAULA: "Marham-e-Khall", KEY ATTRIBUTES OF TKDL MA2/678A, pages 1 - 2, XP003025230 |
KALI DASA: "Lakucadi Yoga", KEY ATTRIBUTES OF TKDL RS14/438, pages 1 - 2, XP003025228 |
MOHD AZAM KHAN: "Zimaad-e-Aahak", KEY ATTRIBUTES OF TKDL MH3/49L, pages 1 - 2, XP003025226 |
MOHD AZAM KHAN: "Zimaad-e-Mudammil", KEY ATTRIBUTES OF TKDL AA26/115C, pages 1 - 2, XP003025229 |
MOHD NAJMUL GHANI KHAN: "Zaroor Bara-e-Qurooh", KEY ATTRIBUTES OF TKDL JA6/1040D, pages 1 - 2, XP003025224 |
MOHD SHAREEF KHAN: "Marham-e-Khall/Jaalinos Bara-e-Qurooh-b", KEY ATTRIBUTES OF TKDL MH1/4111B, pages 1 - 3, XP003025231 |
SUSRUTA: "Vranacikitsa - 02", KEY ATTRIBUTES OF TKDL AT/743, pages 1 - 2, XP003025225 |
VANGASENA: "Sarsapadi Lepa", KEY ATTRIBUTES OF TKDL AK11/2350, pages 1 - 2, XP003025227 |
Also Published As
Publication number | Publication date |
---|---|
IL183117A0 (en) | 2007-10-31 |
CA2588119A1 (en) | 2006-05-26 |
BRPI0517731A (en) | 2008-10-21 |
WO2006055726A2 (en) | 2006-05-26 |
AU2005307736A1 (en) | 2006-05-26 |
WO2006055726A3 (en) | 2007-03-22 |
JP2008520694A (en) | 2008-06-19 |
EP1827466A4 (en) | 2009-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3773764B1 (en) | Composition for treatment of chronic wounds | |
JP6495183B2 (en) | Compositions and methods for treating surface wounds | |
AU2010257466B2 (en) | Epidermal growth factor composition, a process therefor and its application | |
AU2002312416A1 (en) | Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions | |
US8492435B2 (en) | Composition for treating a dermal anomaly | |
JPH09510978A (en) | Starch-metal complex for skin and hair | |
SK287249B6 (en) | Medicinal products with cicatrizing action comprising biguanide derivatives | |
WO2008104076A1 (en) | Electrocolloidal silver and echinacea root antimicrobial formulation | |
KR101451816B1 (en) | Pharmaceutical Composition for Preventing or Treating Diabetic Wound | |
WO1994005272A1 (en) | Skin treatment compositions containing dimethylsulphone and dimethylsulphoxide | |
WO1994005293A1 (en) | Skin treatment compositions containing dimethylsulphone and allopurinol or oxypurinol | |
EP1827466A2 (en) | Composition and method for facilitating the healing of non-healing and slow-healing wounds and ulcerations | |
WO1994005279A1 (en) | Dermatological treatment compositions containing dimethylsulphone and a sulfur containing amino acid | |
US20080045604A1 (en) | Composition and method for facilitating the healing of non-healing and slow-healing wounds and ulcerations | |
EP1397124B1 (en) | Use of antidiabetics for making a medicine with cicatrizing effect | |
Rajashri et al. | Curcuma Longa and Pineapple Extract Paste in the management of Alveolar Osteitis: An Experimental study | |
US20220249543A1 (en) | Trona Based Therapeutic Compositions and Use and Manufacture Thereof | |
US20060105027A1 (en) | Method for treating skin ulcers | |
US20100189668A1 (en) | Composition for treating herpes simplex viral infections, the method, use and process by which the composition is utilized and the manufacture of the composition | |
LV13450B (en) | Novel medicinal use of meldonium and pharmaceutical compositions thereof | |
WO2015159206A1 (en) | Copper alloy microparticles for use in the treatment of an external skin lesion | |
KR20140104932A (en) | Pharmaceutical Composition for Preventing or Treating Diabetic Wound | |
JPH07118165A (en) | Transcutaneous absorption composition containing calcitonin gene relating peptide | |
US20210106646A1 (en) | Combination Of A Novel Topical Gel And Oral Supplements For Healing Diabetic Foot And Other Wounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20070613 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK YU |
|
DAX | Request for extension of the european patent (deleted) | ||
TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20090907 |
|
17Q | First examination report despatched |
Effective date: 20100222 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20120601 |